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THE development of selective PAF receptor antagonists
may provide a novel approach to the treatment of human
bronchial asthma. In preclinical animal models of human
asthma, PAF receptor antagonists have been found to be
efficacious in blocking antigen-induced changes in lung
function. However, the majority of these models involve
acute inflammatory events and transient changes in lung
function and, therefore, their relevance to human asthma
is questionable. In a recent study with a primate model of
chronic airway inflammation and hyperresponsiveness, we
have shown that treatment with a PAF receptor antagonist
had no effect on reducing chronic inflammation and
hyperresponsiveness. Similarly, recent studies in human
asthmatics with PAF receptor antagonists have failed to
show efficacy in blocking allergen-induced airway
responses or to have any steroid sparing effects in patients
with ongoing asthma. Thus, it seems that PAF may not
be a key mediator which can be blocked and thereby
provide therapy for bronchial asthma.
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Bronchial asthma is a disease that affects
approximately 5-8% of the population and despite
the availability of more potent, selective therapies,
the incidence of asthma morbidity and mortality is
increasing. Asthma is a complex disease that is
characterized, in part, by a reversible, episodic
bronchoconstriction and wheeze. The airways of
asthmatics are inflamed and hyperresponsive
making them respond (constrict) to a variety of
stimuli.
Over the past few years it has become
increasingly apparent that asthma has a strong
inflammatory component. This realization has
prompted an intense effort within academia and
industry to define the role of inflammatory cells
and mediators in asthma. The hypothesis that
PAF is an important mediator in the pathophysio-
logy of asthma was initially derived from studies
demonstrating its ability to constrict airway smooth
muscle at very low doses as well as its pro-
inflammatory properties.
2 While the broncho-
constrictive and oedema-inducing effects ofPAF are
shared by other putative mediators of inflammation
such as histamine, thromboxane and leukotrienes,
PAF is the only mediator which simultaneously
increases mucus secretion
3 and recruits platelets and
eosinophils
4 from the extravascular space into the
lungs. Since eosinophils are thought to play an
important role in the pathogenesis of asthma, it is
of interest therefore, that PAF is among the most
potent chemotactic factors for eosinophils. Fur-
thermore, similar to antigen inhalation, inhaled
PAF induces an acute and late-phase response in
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dual responder animals
6 and, in addition, has been
shown to induce bronchial hyperreactivity in
different species including man.
7 Thus, in light of
the biology of PAF, the development of selective
PAF-receptor antagonists seemed most promising
in terms of a novel approach to the treatment Qf
bronchial asthma.
PAF antagonists in preclinical animal models: Studies of
PAF antagonists in preclinical models of asthma
have produced encouraging results demonstrating
potent inhibition of allergen induced bronchocon-
striction, infiltration of eosinophils into the airways,
lung oedema formation, late phase reactions and the
development of nonspecific bronchial hyperre-
sponsiveness. In addition, the formation and release
of inflammatory mediators (including leukotrienes,
prostaglandins, thromboxanes and histamine) have
been shown to be inhibited by selective PAF
receptor antagonists in vivo, although a direct
interaction of the PAF antagonists with these
mediators has been excluded. The role of PAF in a
sequence of pathophysiological events involving
other mediators, and the possibility of interactive
synergism, strengthens the view that antagonists of
PAF may have effects extending beyond those
assumed for a single mediator. In models of in vivo
anaphylaxis the divergent results obtained with
PAF antagonists may be due to differing experi-
mental conditions (e.g. testing in the absence of a
small dose of an antihistamine, antigen load during
challenge, booster sensitization etc.) and the
different potency and bioavailability of PAF
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antagonists in vivo. PAF antagonists seem to work
more consistently in passive anaphylaxis and during
challenge with the antigen by the inhaled route.
8 In
active anaphylaxis PAF antagonists are more
et:fective when animals are once sensitized compared
to a booster sensitization regimen,9’1 however,
PAF antagonists can still block anaphylaxis in
boosted animals.1 With respect to microvascular
permeability, in one set of experiments a PAF
antagonist failed to block leakage at a dose which
inhibited PAF induced microvascular leakage.
11
Other results are in favour of a PAF antagonist
blocking antigen induced microvascular leakage.
12
PAF antagonists block eosinophil and leukocyte
infiltration in the bronchial tissue and appearance
of the cells in bronchoalveolar fluid of sensitized
guinea pigs,
4 rabbits
3 and monkeys.
14 A few studies
have, however, failed to show this effect. Inhibition
of the late phase response to antigen with selective
PAF antagonists has been demonstrated in several
animal models including allergic guinea-pigs,
is
rabbits,
16 sheep
6 and monkeys.
14 Inhibition of
antigen increased bronchial responsiveness by
selective PAF antagonists has been reported by
several groups in guinea-pigs,
11 rabbits
3 and other
species.
17 The experimental conditions in the studies
cited above involve a single antigen challenge to
sensitized animals with normal (uninflamed) lungs
and the relevance of these preclinical models to
human bronchial asthma remains unclear.
PAF antagonists in clinical studies" In contrast to
supportive results from preclinical models of
asthma, the clinical data obtained so far are not in
favour of a major role of PAF in human bronchial
asthma.-2 Despite the fact that several clinical
studies have documented that PAF antagonists
block exogenous PAF induced et:fects in man,21’22
oral or inhaled PAF antagonists have failed to block
antigen induced early or late phase responses or
increases in bronchial responsiveness. In addition,
there is also no support for clinical efficacy from a
recent phase II steroid sparing study in ongoing
human bronchial asthma (S. Holgate, personal
communication). One may speculate on the possible
reasons for the discrepancy between supportive
preclinical results and failure of PAF antagonists in
clinical human asthma. The first and most obvious
conclusion that can be drawn from the clinical data
is that, in contrast to ditCferent animal species
(including monkeys), PAF is not an important
mediator in human asthma. Secondly, although
there is no convincing evidence that different
subtypes’0f PAF receptors exist in lung tissue and
inflammatory cells present in lung tissue, there may
be subtypes ofPAF receptors including intracellular
receptors with varying affinities for PAF and PAF
antagonists. This question deserves further investi-
gation. Third, due to priming and synergism of
PAF with other mediators of inflammation
produced during chronic asthma, the doses of PAF
antagonists needed may be far higher than those
needed to antagonize exogenous PAF.23 However,
it is also conceivable that a high dose therapy of
PAF antagonists may result in an up-regulation of
PAF receptors or expression of other ligands
involved in the inflammatory process. This latter
point emphasizes the importance of the dosing
regimen and the possibility of a rebound
phenomenon. Finally, the question remains open
whether only subtypes of asthma (severe, mild,
intrinsic, extrinsic) are sensitive to PAF antagonists
and whether the appropriate clinical target
parameter has been addressed in recent clinical
studies. This complexity of disease diagnosis further
illustrates and exposes the limitations of preclinical
models.
In conclusion, based on available clinical studies
so far, it seems that platelet activating factor is not
a key mediator which can be blocked and thereby
provide therapy in human bronchial asthma.
However, several critical questions of its physio-
logical function remain unanswered. In preclinical
settings PAF antagonists have only been shown to
be eective in single challenge, acute disease related
models when the action of other mediators could
be inhibited indirectly via their release being
subsequent to a synergism with PAF. These data
could be interpreted that an obvious limitation of
all preclinical models is the lack of a baseline
chronic airway inflammatory setting. It may well
reflect that there is a basic, underlying abnormality
in lung function which influences, in part, the
release and actions of inflammatory mediators. It
needs to be demonstrated that in humans, the
antagonism ofPAF goes beyond the antagonism, of
this single mediator to have implications for any
disease including bronchial asthma. It seems
unlikely that the transient release of a single
mediator or transient cell infiltrate may account for
the complex pathophysiology of bronchial asthma.
Bronchial asthma is a chronic disease and the results
of a study from our laboratory with a PAF
antagonist reported in this issue illustrates the
possible limitations of preclinical models and the
potential dangers of too little information.
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